Manx Financial Regulatory News (MFX)

IMMEDIATE RELEASE 7 February 2018

Manx Financial Group PLC

(the "Group")

Board Appointment

The board of Manx Financial Group PLC is delighted to announce the appointment of Dr Greg Bailey as a Non-Executive Director with immediate effect.

Greg Bailey, M.D., founded Palantir Group Inc which made successful investments in bio-tech company start-ups and financings, and is currently chairman of Portage Biotech Inc, a CSE-traded drug development company, and non-executive director of AIM-traded SalvaRx Group Plc. Along with comprehensive experience in finance and healthcare, Greg has served on many public company boards and brings to the Group an extensive involvement in corporate governance.

Denham Eke commented: "We welcome Greg to the Board, and look forward to benefiting from his breadth of knowledge as well as his understanding of financing and investments".

Current and past Directorships for Gregory Hugh Bailey, aged 62, are set out below:

Dr Bailey is indirectly interested in 17,835,750 ordinary shares, representing 13.60% of the issued share capital of Manx Financial Group PLC.

There is no further information relating to Dr Bailey required to be disclosed under Schedule Two, (g) (i)-(viii).

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014

For further information, please contact:

Manx Financial Group PLC

Denham Eke, Chief Executive

Tel: +44 (0) 1624 694694

Beaumont Cornish Limited

Roland Cornish/James Biddle

Tel: +44 (0) 20 7628 3396

Britton Financial PR

Tim Blackstone

Tel: +44 (0) 7957 140416